Trial Profile
Optimal Prevention of Overdose Deaths and Opioid Relapse Following Discharge: A Multi-Center RCT of Naltrexone Versus Buprenorphine in Norway
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Naltrexone (Primary) ; Buprenorphine/naloxone; Buprenorphine/naloxone
- Indications Opioid-related disorders
- Focus Therapeutic Use
- Acronyms NTX-SBX
- 01 Dec 2023 Results (n=143; November 2012, and July 2016) assessing compensatory increase in use of non-opioid illicit substances and alcohol in opioid dependent patients randomized to treatment with extended-release naltrexone (XR-NTX) or buprenorphine-naloxone (BP-NLX) and in longer term treatment with extended-release naltrexone, published in the Contemporary Clinical Trials.
- 19 Dec 2018 Results published in the JAMA Psychiatry
- 10 Oct 2018 Status changed from active, no longer recruiting to completed.